[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620462":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":22,"locations":22,"responsibleParty":23,"collaborators":27,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":22,"eligibilityCriteria":38,"healthyVolunteers":35,"sex":39,"minAge":40,"maxAge":22,"enrollmentInfo":41,"targetDuration":22,"studyType":44,"phases":45,"briefSummary":48,"conditions":49,"keywords":22,"overallStatus":52,"whyStopped":22,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":22},{"fullName":5,"class":6},"China-Japan Friendship Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Standardized Methylprednisolone Intervention (Dose-Adjusted)","EXPERIMENTAL","All enrolled patients receive intravenous methylprednisolone (0.5-1 mg\u002Fkg\u002Fday, dissolved in 100ml normal saline, once daily) for a total of 7 days. The initial dose is determined by the oxygenation index (PFR) at enrollment:\n\n* PFR ≤ 150 mmHg: Methylprednisolone 1 mg\u002Fkg\u002Fday.\n* PFR \\> 150 mmHg: Methylprednisolone 0.5 mg\u002Fkg\u002Fday.\n\nAt day 4 (D4), the dose is halved if the patient shows a clinical response (defined as an improvement in the oxygenation index ≥20% AND a decrease in SOFA score ≥2 points); otherwise, the original dose is maintained. Methylprednisolone is discontinued upon death or transfer out of the ICU. All patients also receive standard care for bacterial CAP-ARF as determined by the treating physician.",[13],"Drug: Methylprednisolone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Methylprednisolone","This is the core intervention. For detailed dosage, administration, and dose-adjustment strategy, please refer to the Arm Description.",[9],[21],"Solu-Medrol",null,{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"SPONSOR_INVESTIGATOR","Qingyuan Zhan","Director",[28,30],{"name":29,"class":6},"The First Affiliated Hospital of Guangzhou Medical University",{"name":31,"class":32},"Wuhan Metware Biotechnology Co., Ltd.","UNKNOWN","100620462","phase-1-early-inflammatory-immune-stratification-and-precision-glucocorticoid-intervention-in-acute-respiratory-failure-induced-by-community-acquired-pneumonia-100620462",false,"NCT07357935","Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced by Community-Acquired Pneumonia","Inclusion Criteria:1. Age ≥ 18 years. 2. Admitted to the Intensive Care Unit (ICU) within 48 hours. 3. Meet diagnostic criteria for bacterial community-acquired pneumonia (CAP). 4. Meet at least one severity criterion: a) Receiving mechanical ventilation for acute respiratory failure with PEEP ≥ 5 cmH2O; OR b) On high-flow oxygen with FiO2 ≥ 0.5 and PaO2\u002FFiO2 ratio ≤ 250 mmHg; OR c) On a reservoir oxygen mask with PaO2 below the specified flow threshold (see protocol). 5. Signed informed consent.\n\n\\-\n\nExclusion Criteria: 1. Suspected aspiration pneumonia. 2. Invasive mechanical ventilation within 14 days prior to admission. 3. Diagnosis of hospital-acquired or ventilator-associated pneumonia (HAP\u002FVAP). 4. Positive for influenza virus, active tuberculosis, or fungal infection (except Pneumocystis jirovecii). 5. Active viral hepatitis or herpesvirus infection. 6. Hypersensitivity to glucocorticoids, or contraindications as judged by the investigator (e.g., severe concurrent infections, active gastrointestinal hemorrhage). 7. High-dose glucocorticoid therapy (\\>1 mg\u002Fkg\u002Fday prednisone equivalent) within 30 days for underlying disease. 8. Death within 24 hours of ICU admission. 9. Pregnancy or lactation. 10. Participation in other interventional studies or refusal to participate.\n\n\\-","ALL","18 Years",{"count":42,"type":43},500,"ESTIMATED","INTERVENTIONAL",[46,47],"PHASE1","PHASE2","This is a prospective, multicenter, interventional cohort study aimed at constructing a high-quality, dynamic multimodal database for patients with acute respiratory failure caused by community-acquired pneumonia (CAP-ARF). The study focuses on bacterial CAP-ARF patients receiving standardized glucocorticoid therapy to investigate the heterogeneity of treatment responses under different etiologies and immune statuses. The goal is to provide a data foundation for precise immune stratification and identification of glucocorticoid-sensitive populations.",[50,51],"Acute Respiratory Failure","Community-Acquired Pneumonia","NOT_YET_RECRUITING","2026-01-14",{"date":55,"type":56},"2026-01-22","ACTUAL",{"date":58,"type":43},"2026-02-01",{"date":60,"type":43},"2028-10-01",{"name":25,"class":6}]